Dexamethasone/Levofloxacin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Dexamethasone/Levofloxacin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Dexamethasone/Levofloxacin can convert its Small molecule drug profile and Bacterial Top II x GR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Dexamethasone/Levofloxacin (query alias: Dexamethasone/Levofloxacin) |
|---|---|
| Modality / target | Small molecule drug; Bacterial Top II x GR; Bacterial DNA gyrase inhibitors, GR agonists |
| Highest global status | Approved |
| Originator | NTC SRL |
| Active developers | Santen SAS, Xediton Pharmaceuticals, Inc., Tubilux Pharma SpA |
The MCP disease footprint includes Eye Infections, Bacterial, Ocular inflammation, Cataract. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07722091 | Not Applicable | Not yet recruiting | 584 | Incidence of postoperative hoarseness within 10 days |
| JPRN-jRCT1052260116 | Not Applicable | 募集中 | 116 | Change in the total QoR-15J score from the preoperative baseline (at the time of anesthesia consent acquisition, up to the day before surgery) to POD1 (within 24 hours after the end of surgery) |
| ChiCTR2600128651 | Not Applicable | Not yet recruiting | 47 | 12-month recurrence rate of uveitis |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase II Study of Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
Phase 2; n=56; evaluation: not stated. Reported fields: -; -; -
A Phase II Study of Induction Systemic mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone Given Concurrently With Systemic mFOLFIRI as a First-Line Therapy in Patients With Unresectable Liver-Dominant Intrahepatic Cholangiocarcinoma
Phase 2; n=5; evaluation: not stated. Reported fields: -; Frequency of Abnormal Liver Function = 0 Participants ; -
Treatment of Headache With Occipital Nerve Blocks: Comparison Trial of Anesthetic With or Without Dexamethasone
Phase 4; n=120; evaluation: not stated. Reported fields: -; -; Change in Headache Days 1 Week Following Treatment(Mean) = -1.8 days (Standard Deviation, 2.2)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Dexamethasone/Levofloxacin addresses Eye Infections, Bacterial, Ocular inflammation, Cataract. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-07-24 | Quince Therapeutics Completes Acquisition of EryDel S.p.A. | Phase 3 | US$485.0M milestones |
| 2022-06-13 | Endo partners with TLC BioSciences to market TLC-599 for osteoarthritis pain in the US. | Phase 3 | US$30.0M upfront; US$110.0M milestones; US$140.0M stated total |
| 2015-07-10 | EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
